Takeda on Medical Innovation and Net Zero Strategy

As a company that has achieved its goal of being carbon neutral by 2020, global biopharmaceutical company Takeda is well aware of its mission to protect the planet as public health is closely linked to environmental quality. In addition to focusing on implementing many policies and programs to protect people and the earth, Takeda also strives to bring preventive therapies for infectious diseases that are increasing due to climate change, including a dengue vaccine.

Takeda's factory in Germany.

From carbon neutral to Net Zero by 2035

To achieve its goal of carbon neutrality by 2020, Takeda has invested in more than 30 projects across 12 countries. These projects utilize wind and solar energy, improve clean water sources, and conserve forests and biodiversity, targeting 15 of the 17 United Nations Sustainable Development Goals.

A typical example is the project to build and repair a well system for the Republic of Malawi (Africa), providing clean water and reducing dependence on firewood for water heating, thereby limiting deforestation. In rural areas in China, the company has supported the replacement of coal stoves with solar stoves, both improving air quality and ensuring people's living needs. In addition, Takeda has also supported the conservation of more than 8,600 hectares of forest in Tennessee, USA and implemented a sustainable forest management program in Japan.

Going further, Takeda aims to achieve net zero carbon emissions within the company by 2035 and across the entire value chain by 2040. This strategy includes eliminating at least 90% of emissions, while also investing in direct carbon capture technology or planting new forests.

Takeda’s BioLife Plasma Donation Center in Linz, Austria, for example, has been completely converted to run on zero-emission electric power. The company has also committed to using 40% electric or hybrid vehicles by 2025, aiming to completely eliminate internal combustion engine vehicles by 2030.

Takeda scientists

In 2023, Takeda opened its first positive energy plant in Singapore, and was certified with BCA Green Mark Platinum Positive Energy status.

Environmental conservation efforts are also supported by all employees at Takeda. Applying advanced technology, data science and inherent creative thinking, the team has implemented many projects to optimize the use of clean water and natural gas in the production process. Takeda also actively recycles and reuses to minimize the amount of waste released into the environment. According to the 2024 report, 78% of waste is treated optimally, avoiding landfills.

A key element of the Net Zero strategy is partner engagement. According to internal figures, 87% of emissions come from supply chain partners. By the end of 2023, 53% of Takeda’s product packaging will be from recycled sources or certified to meet sustainability standards, contributing to reducing waste. Takeda is currently on track to have 67% of its suppliers meet their emissions reduction targets by the end of 2024. In addition, to significantly reduce its carbon footprint in transportation, 50% of the company’s goods will be shipped by sea instead of air.

Takeda's Singapore plant produces more energy than it consumes.

Responding to dengue fever - an important contribution to the prevention of diseases increasing due to climate change

Climate change is one of the leading causes that makes dengue fever more dangerous. The World Health Organization (WHO) considers this disease a top health threat in the world, including Vietnam.

While vector control and mosquito bite avoidance measures are important, WHO recommends a comprehensive strategy that includes vaccination to minimize the impact of disease outbreaks. Building on more than 70 years of experience in the vaccine field in Japan, Takeda has expanded this effort globally in recent years, providing solutions and cooperation for sustainable prevention of infectious diseases such as dengue.

In conjunction with the COP28 International Conference in Dubai, Takeda, in collaboration with the World Mosquito Programme (WMP), Johnson & Johnson and other partners, organized the “International Dengue Forum: Seven Innovations for Dengue Prevention and Control in a New Landscape”. The conference brought together multidisciplinary experts in environmental science, vaccines and climate change to discuss and promote joint action to combat the growing threat of dengue. Following the event, Takeda released reports to strengthen support for long-term dengue prevention initiatives globally.

After being licensed for circulation, in September 2024, Takeda's tetravalent dengue vaccine was officially deployed in Vietnam. This is the first vaccine to prevent this disease in Vietnam.

Takeda’s dengue vaccine has been approved in more than 40 countries around the world, including the European Union, Colombia, Thailand, Malaysia and Vietnam. In some countries, such as Brazil, Argentina and Indonesia, people can access the vaccine through provincial and national vaccination programs.

Takeda’s strategy harmoniously combines sustainable development and providing practical medical solutions, creating a typical model in the pharmaceutical industry. The group’s efforts not only affirm its pioneering role in medical innovation but also contribute to improving the quality of life of people in Vietnam and around the world.

Medical information

This information is for informational purposes only; and should not be used to diagnose or treat a health problem or disease. It is not intended to replace consultation with a physician. Please consult your physician for further advice.

Link to view the entire APEC 2024 special issue, including the article (bilingual English - Vietnamese) about Takena.

Source: https://baoquocte.vn/takeda-voi-doi-moi-y-te-va-chien-luoc-net-zero-293042.html